These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 6120481)

  • 1. Peptide-monoamine coexistence: studies of the actions of cholecystokinin-like peptide on the electrical activity of midbrain dopamine neurons.
    Skirboll LR; Grace AA; Hommer DW; Rehfeld J; Goldstein M; Hökfelt T; Bunney BS
    Neuroscience; 1981; 6(11):2111-24. PubMed ID: 6120481
    [No Abstract]   [Full Text] [Related]  

  • 2. Tyrosine hydroxylase and cholecystokinin mRNA levels in the substantia nigra, ventral tegmental area, and locus ceruleus are unaffected by acute and chronic haloperidol administration.
    Cottingham SL; Pickar D; Shimotake TK; Montpied P; Paul SM; Crawley JN
    Cell Mol Neurobiol; 1990 Mar; 10(1):41-50. PubMed ID: 1970757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Midbrain dopamine neurons: differential responses to amphetamine isomers.
    Browder S; German DC; Shore PA
    Brain Res; 1981 Mar; 207(2):333-42. PubMed ID: 7470912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haloperidol induces persistent down-regulation of tyrosine hydroxylase immunoreactivity in substantia nigra but not ventral tegmental area in the rat.
    Levinson AJ; Garside S; Rosebush PI; Mazurek MF
    Neuroscience; 1998 May; 84(1):201-11. PubMed ID: 9522374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The dopaminergic nigropallidal projection in primates: distinct cellular origin and relative sparing in MPTP-treated monkeys.
    Parent A; Lavoie B; Smith Y; Bédard P
    Adv Neurol; 1990; 53():111-6. PubMed ID: 1978512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of methamphetamine on dopamine cells in the substantia nigra pars compacta and the ventral tegmental area.
    Kamata K; Kameyama T
    Jpn J Pharmacol; 1985 Jun; 38(2):231-4. PubMed ID: 4032860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ventral mesencephalic neurons containing both cholecystokinin- and tyrosine hydroxylase-like immunoreactivities project to forebrain regions.
    Seroogy KB; Dangaran K; Lim S; Haycock JW; Fallon JH
    J Comp Neurol; 1989 Jan; 279(3):397-414. PubMed ID: 2563737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irreversible receptor inactivation reveals differences in dopamine receptor reserve between A9 and A10 dopamine systems: an electrophysiological analysis.
    Cox RF; Waszczak BL
    Brain Res; 1990 Nov; 534(1-2):273-82. PubMed ID: 1981482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of [3H]-dopamine binding by cholecystokinin octapeptide (CCK-8).
    Murphy RB; Schuster DI
    Peptides; 1982; 3(3):539-43. PubMed ID: 6289286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppressive effect of L-dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine.
    Blunt SB; Jenner P; Marsden CD
    Mov Disord; 1993 Apr; 8(2):129-33. PubMed ID: 8097279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of N-n-propylnorapomorphine enantiomers on single unit activity of substantia nigra pars compacta and ventral tegmental area dopamine neurons.
    Cox RF; Neumeyer JL; Waszczak BL
    J Pharmacol Exp Ther; 1988 Oct; 247(1):355-62. PubMed ID: 3171980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dissociated high-purity dopaminergic neuron cultures from the substantia nigra and the ventral tegmental area of the postnatal rat.
    Masuko S; Nakajima S; Nakajima Y
    Neuroscience; 1992 Jul; 49(2):347-64. PubMed ID: 1359454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the effects of the cholecystokinin-B receptor antagonist, PD 134308, and the cholecystokinin-A receptor antagonist, L-364,718, on dopamine neuronal activity in the substantia nigra and ventral tegmental area.
    Meltzer LT; Christoffersen CL; Serpa KA; Razmpour A
    Synapse; 1993 Feb; 13(2):117-22. PubMed ID: 8446920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Responses of intracellularly recorded cortical neurons to the iontophoretic application of dopamine.
    Bernardi G; Cherubini E; Marciani MG; Mercuri N; Stanzione P
    Brain Res; 1982 Aug; 245(2):267-74. PubMed ID: 6289964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced dopamine metabolism in accumbens leads to motor activity and concurrently to increased output from nondopamine neurons in ventral tegmental area and substantia nigra.
    Olds ME
    Physiol Behav; 1992 Jan; 51(1):39-50. PubMed ID: 1311110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of the actions of phencyclidine on midbrain dopamine neurons.
    French ED; Levenson S; Ceci A
    NIDA Res Monogr; 1989; 95():255-63. PubMed ID: 2561830
    [No Abstract]   [Full Text] [Related]  

  • 17. Dopamine agonist potencies of ergolines.
    Lew JY; Nakamura S; Battista AF; Goldstein M
    Commun Psychopharmacol; 1979; 3(3):179-83. PubMed ID: 115634
    [No Abstract]   [Full Text] [Related]  

  • 18. Electrophysiological effects of cholecystokinin on neurons in rat substantia nigra pars reticulata.
    Zhang J; Freeman AS
    Brain Res; 1994 Jul; 652(1):154-6. PubMed ID: 7953713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The behavioural effects of a novel substance P analogue following infusion into the ventral tegmental area or substantia nigra of rat brain.
    Eison AS; Eison MS; Iversen SD
    Brain Res; 1982 Apr; 238(1):137-52. PubMed ID: 6177380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The neurotensin analog xenopsin excites nigral dopamine neurons.
    Pozza MF; Küng E; Bischoff S; Olpe HR
    Eur J Pharmacol; 1988 Jan; 145(3):341-3. PubMed ID: 3350051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.